Private patients in the UK face a steep rise in the cost of Eli Lilly's diabetes and weight-loss drug Mounjaro, with prices set to increase by up to 170 per cent from September 2025.
While National Health Service (NHS) patients will continue to access the medicine at current rates under a separate supply arrangement, those paying privately could see the cost for the highest dose rise from about £122 to £330 a month. Clinicians and pharmacists have warned the increase could affect affordability and patient adherence.
